KDKurt Derfler

Kurt Derfler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kurt Derfler has a total of 508 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis

    by Georgiana-Aura Giurgea, Elodie Karkutli, Susanne Granegger, Robert Berent, Kurt Derfler, Helmut Sinzinger


  • Therapeutic Plasma Exchange and Immunoadsorption: Indications and Implementation

    by Ammon Handisurya, Christof Aigner, Benjamin Schairer, Kurt Derfler


  • Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment

    by Kurt Derfler, Sabine Steiner, Helmut Sinzinger

    The prevalence of familial disorders of lipid metabolism in Europe is higher than believed so far. In severely affected patients in whom conventional combined lipid lowering agents are insufficient to achieve target values, patients being intolerant to all the available members of the statin family as well as in patients with elevated lipoprotein(a) (100 mg/dl) and progression of atherosclerotic vascular disease, despite even normal low-density lipoproteins (LDL)-cholesterol values, lipoprotein-apheresis treatment is indicated. The Austrian Apheresis Consensus compares the inclusion criteria for patients to be treated in Austria with those from Italy, Germany, Spain, Japan, UK and the United States. The cut off level of 100 mg/dl for lipoprotein(a) is higher in Austria as compared to the aforementioned countries (50 or 60 mg/dl, respectively). The available clinical data reveal that regular weekly lipoprotein apheresis not only results in a significant lowering of the respective atherogenic lipid and lipoprotein parameters, but also in a significant decrease in clinical events and interventions. The underlying mechanisms such as non-lipid effects, side effects as well as the different available treatment principles are compared. For patients meeting the inclusion criteria, lipoprotein apheresis is a safe and effective therapy significantly reducing vascular events.


  • Variation of lipoprotein(a) plasma levels after premature myocardial infarction

    by Georg Goliasch, Franz Wiesbauer, Hermann Blessberger, Gerald Maurer, Kurt Derfler, Walter S. Speidl


  • Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation—Results of a randomized controlled crossover study

    by Peter Biesenbach, Farsad Eskandary, Cihan Ay, Marion Wiegele, Kurt Derfler, Eva Schaden, Helmuth Haslacher, Rainer Oberbauer, Georg A. Böhmig

    The combined use of immunoadsorption (IA) and membrane filtration (MF) may markedly enhance removal of IgM and complement component C1q, supporting its use as an element of recipient desensitization in antibody‐incompatible transplantation. However, coagulation factor removal may contribute to altered hemostasis, posing a risk of bleeding in the perioperative setting. This secondary endpoint analysis of standard coagulation assays and rotational thromboelastometry (ROTEM®) was performed in the context of a randomized controlled crossover study designed to assess the effect of combined IA (GAM‐146‐peptide) and MF on levels of ABO antigen‐specific IgM. Fourteen patients with autoimmune disorders were randomized to a single treatment with IA+MF followed by IA alone, or vice versa. MF was found to markedly enhance fibrinogen depletion (57% vs. 28% median decrease after IA alone,P < 0.001), whereby four patients showed post‐treatment fibrinogen concentrations below 100 mg dL−1. In support of a critical contribution of fibrinogen depletion to impaired coagulation, extrinsically activated ROTEM®analysis revealed a marked reduction in fibrinogen‐dependent clot formation upon IA+MF (59% median decrease in FIBTEM mean clot firmness (MCF) as compared to 24% after IA alone,P < 0.001). Moreover, the addition of MF led to a substantial prolongation of activated partial thromboplastin time, possibly due to depletion of macromolecular coagulation factors contributing to intrinsically activated coagulation. Our study demonstrates substantial effects of combined IA+MF on clot formation, which may be mainly attributable to fibrinogen depletion. We suggest that the use of combined apheresis in the setting of transplant surgery may necessitate a careful monitoring of coagulation. J. Clin. Apheresis 31:29–37, 2016.


  • Fibrinogen Reduction and Bleeding Complications in Plasma Exchange, Immunoadsorption and a Combination of the Two

    by Simon Zöllner, Eleonore Pablik, Wilfred Druml, Kurt Derfler, Andrew Rees, Peter Biesenbach

    Background: Immunoadsorption (IAS) and therapeutic plasma exchange (TPE) are considered safe although fibrinogen is removed. To date no comparison of fibrinogen reduction and associated risk of bleeding in apheresis exists. Methods: Retrospective analysis of TPE, three IAS adsorbers, and combined TPE/IAS regarding fibrinogen reduction and bleeding incidence in 67 patients (1,032 treatments). Results: TPE and TPE/IAS reduced fibrinogen by 64 ± 11% and 58 ± 9%, leading to concentrations <100 mg/dl in 20 and 17% of treatments, respectively. IAS decreased fibrinogen less than TPE (26 ± 6%, p < 0.0001), resulting in fibrinogen concentrations <100 mg/dl in 1% of treatments. The processed volume correlated with reduction in TPE (r = 0.64, p < 0.01), but not in IAS. Bleeding occurred in 1.3% (IAS), 2.3% (TPE) and 3.1% (TPE/IAS) of treatments. Conclusion: Hypofibrinogenemia occurs in 20% of patients after TPE and TPE/IAS, but rarely after IAS. IAS removes fibrinogen independently of volume processed. Overall, bleeding is rare in apheresis.


  • Open Access

    Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Immunoadsorption

    by Peter Biesenbach, Renate Kain, Kurt Derfler, Thomas Perkmann, Afschin Soleiman, Alexandra Benharkou, Wilfred Druml, Andrew Rees, Marcus D. Säemann

    Anti-glomerular basement membrane (GBM) antibody disease may lead to acute crescentic glomerulonephritis with poor renal prognosis. Current therapy favours plasma exchange (PE) for removal of pathogenic antibodies. Immunoadsorption (IAS) is superior to PE regarding efficiency of antibody-removal and safety. Apart from anecdotal data, there is no systemic analysis of the long-term effects of IAS on anti-GBM-disease and antibody kinetics. To examine the long-term effect of high-frequency IAS combined with standard immunosuppression on patient and renal survival in patients with anti-GBM-disease and to quantify antibody removal and kinetics through IAS. Retrospective review of patients treated with IAS for anti-GBM-antibody disease confirmed by biopsy and/or anti-GBM-antibodies. University Hospital of Vienna, Austria. 10 patients with anti-GBM-disease treated with IAS. Patient and renal survival, renal histology, anti-GBM-antibodies. Anti-GBM-antibodies were reduced by the first 9 IAS treatments (mean number of 23) to negative levels in all patients. Renal survival was 40% at diagnosis, 70% after the end of IAS, 63% after one year and 50% at the end of observation (mean 84 months, range 9 to 186). Dialysis dependency was successfully reversed in three of six patients. Patient survival was 90% at the end of observation. IAS efficiently eliminates anti-GBM-antibodies suggesting non-inferiority to PE with regard to renal and patient survival. Hence IAS should be considered as a valuable treatment option for anti-GBM-disease, especially in patients presenting with a high percentage of crescents and dialysis dependency due to an unusual high proportion of responders.


  • Open Access

    ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial

    by Farsad Eskandary, Markus Wahrmann, Peter Biesenbach, Camilla Sandurkov, Franz König, Elisabeth Schwaiger, Thomas Perkmann, Sarojinidevi Künig, Kurt Derfler, Gerhard J. Zlabinger, et al.

    Potent antibody depletion techniques have paved the way to successful ABO-incompatible transplantation. Considering its efficiency regarding IgG removal, the use of non-antigen-specific semi-selective immunoadsorption (IA) has been advocated. One attractive strategy to overcome the caveat of incomplete IgM depletion and to interfere with complement activation could be the adjunctive use of membrane filtration (MF) to enhance the removal of macromolecules. To investigate the depletion efficiency of semi-selective IA plus MF, we conducted a randomized, controlled, cross-over trial including patients on regular IA treatment for indications outside recipient desensitization. According to the results of sample size calculation, 14 subjects were enrolled. Two treatment sequences, a single session of IA plus MF followed by IA alone after ≥7 days (and vice versa), were analysed. IA plus MF markedly enhanced the median per cent reduction of ABO-specific IgM determined by flow cytometry (primary end point; 59 versus 23%, P < 0.001) and haemagglutination (2 versus 1 titre steps, P < 0.001), respectively. Combined treatment also substantially lowered C1q concentrations (86 versus 58% reduction, P < 0.001) and the functionality of classical complement as reflected by impaired in vitro C3 activation capability. IgG was strongly reduced without any additional effect of MF. We demonstrate that the innovative strategy of combining MF with semi-selective IA may substantially increase IgM elimination and affect classical complement activation. Our findings suggest that this new treatment concept could be an efficient strategy for recipient desensitization in ABO- and HLA-incompatible transplantation.


  • THU0282 Immunoadsorption in Lupus Nephritis: Three Different High Affinity Columns are Equally Effective in Inducing Remission

    by P. Biesenbach, K. Derfler, J. Smolen, G. Stummvoll

    Background Pathogenic autoantibodies and immune complexes are a hallmark of SLE and are effectively removed by immunoadsorption (IAS). We previously reported that IAS performed with columns using sheep IgG as ligand (Ig-Therasorb®) reduces proteinuria and global disease activity in highly active renal SLE (Ref.1). Meanwhile, three different IAS columns using different adsorbing ligands are in use for lupus patients. Objectives We now attempted to answer the question if one column should be preferred in the treatment of active, refractory lupus nephritis. Methods All patients with histologically proven lupus nephritis undergoing IAS (n=26) were included to analyze the effects of IAS during induction therapy (≤3 months) on renal outcome and global disease activity. Patients were grouped according to the IAS column used: IgG-group (sheep IgG, Ig-Therasorb®, n=16), ProtA-group (staphylococcal protein A, Immunosorba®, n=5), and Gam-group (synthetic peptid Gam146, Globaffin®, n=5). Patients underwent IAS therapy when cyclophosphamide or MMF therapy was not effective or contraindicated; characteristics are given in the table. As described, we used response criteria R20 and R50, defined as a reduction by 20% or 50% in at least 2 of the 3 main outcome parameters proteinuria, SLEDAI and pre-treatment anti-dsDNA levels (Ref 1). Results In all 3 groups, IASsignificantly lowered serum levels of IgG, IgM, and anti-dsDNA-abs. Proteinuria significantly decreased in all groups, with a reduction by 48% in IgG versus 67% in ProtA and 64% in Gam groups, respectively (p=n.s.), while serum-creatinine decreased accordingly (table). All groups presented with comparably high disease activity scores (SLEDAI) and achieved a significant reduction within one month. After 3 months, all groups showed good responses with a R20 in >80% and a R50 in >60% of patients. No severe adverse event (allergic reaction, critical hypotension) occurred. Infections were distributed equally among the 3 groups with one infection per patient year necessitating antibiotics. Conclusions IAS reduces proteinuria and global disease activity in refractory lupus nephritis and improves renal function. All three columns performed well in induction therapy with slightly, albeit not significantly better response rates for ProtA and Gam columns. Our findings on efficacy of different columns may facilitate future attempts for randomized controlled trials on IAS in lupus nephritis References Stummvoll et al;IgG immunoadsorption reduces SLE activity and proteinuria: a long term observational study. ARD Juli 2005 Disclosure of Interest None Declared


  • Panorama of adverse events during cytapheresis

    by B. Stegmayr, J. Ptak, T. Nilsson, G. Berlin, V. Mirea, C.G. Axelsson, A. Griskevicius, P. Centoni, G. Liumbruno, J. Audzijoniene, et al.